Related Experiment Video
Updated: Apr 26, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
Association between transforming growth factor-β1gene-509C/T polymorphism and susceptibility of IgA nephropathy: a
Zhanzhan Li1, Yanyan Li, Lizhang Chen
1Department of Epidemiology and Health Statistics, School of Public Health, Central South University , Changsha, Hunan Province , China and.
Abstract:
A role for transforming growth factor-β1gene has been suggested in the etiology of IgA nephropathy. However, results have been inconsistent. In this study, a meta-analysis was performed to further clarify the association between transforming growth factor-β1-509C/T gene polymorphism and the susceptibility of IgA nephropathy. PubMed, EMBASE, Web of Science, CNKI, WanFang, and VIP Data were searched for eligible studies. Pooled odds ratios (ORs) with 95% confidence intervals were calculated using a fixed-effects model or random-effects model. A total of eight publications involving 1355 IgA nephropathy patients and 1464 controls met the inclusion and were analyzed. The pooled ORs for the association between TGF-β1gene-509C/T polymorphism and IgA nephropathy risk were not statistically significant under all genetic models (for CT+TT vs. CC: OR = 1.09; 95% CI = 0.92-1.29, p = 0.490; for TT vs. CT+CC: OR = 1.14; 95% CI = 0.94-1.38, p = 0.081; for CC vs. TT: OR = 0.87; 95% CI = 0.69-1.08, p = 0.195; for C allele vs. T allele: OR = 0.92; 95% CI = 0.83-1.03, p = 0.149). In the stratified analysis by ethnicity, results also showed no significant association between TGF-β1 gene-509C/T polymorphism and IgA nephropathy risk in both European and Asian populations. This meta-analysis does not support the hypothesis that TGF-β1 gene-509C/T polymorphism is a risk factor for the development of IgA nephropathy.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
TGF - β Signaling Pathway
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenomics: Identification of New Drug Targets
Inflammatory Bowel Disease III: Crohn's Disease

